A phase 2 multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

ATG responsive
- T-cell-mediated bone marrow injury

transitional period for T-cell function
- 23 months

ATG non-responsive
- T-cell-mediated anti-tumor immunity

variables favoring ATG response
- shorter disease duration
- % Ki67 on CD4⁺ T-cells
- % terminal memory CD8⁺ cells

variables associated with ATG failure
- longer disease duration
- bone marrow fibrosis
- more than 2 prior MDS therapies

Komrokji et al., Haematologica, 2014